OncoMatch/Clinical Trials/NCT05071937
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Is NCT05071937 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ZEN003694 and Talazoparib for ovarian cancer.
Treatment: ZEN003694 · Talazoparib — This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 any tested
Known BRCA1/2 status
Required: BRCA2 any tested
Known BRCA1/2 status
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: PARP inhibitor — maintenance or therapeutic
Prior therapy with PARPi either as maintenance or therapeutic settings.
Cannot have received: BET inhibitor (ZEN003694)
Have previously received an investigational BET inhibitor (including previous participation in studies with Zenith drug, ZEN003694)
Lab requirements
Blood counts
Hemoglobin 9.0 gm/dL without transfusions during the 4 weeks prior to Screening; ANC 1.5 d7 10^9/L; Platelet count 150,000/mm3
Kidney function
Serum Creatinine 1.5 X ULN
Liver function
AST or ALT 2.0 x ULN or if liver function abnormalities due to liver metastases AST and ALT 5.0 x ULN; Total bilirubin 1.5 x ULN ( 3.0 x ULN for subjects with known Gilbert's syndrome)
Cardiac function
QTcF interval 470 msec
Adequate laboratory parameters at Screening including: Hemoglobin 9.0 gm/dL without transfusions during the 4 weeks prior to Screening; ANC 1.5 d7 10^9/L; Platelet count 150,000/mm3; AST or ALT 2.0 x ULN or if liver function abnormalities due to liver metastases AST and ALT 5.0 x ULN; Total bilirubin 1.5 x ULN ( 3.0 x ULN for subjects with known Gilbert's syndrome); Serum Creatinine 1.5 X ULN; Prothrombin time (PT), INR and PTT < 1.5 x ULN; QTcF interval 470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pittsburgh Medical Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify